Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Minnesota DOH reports first U.S. case of COVID-19 variant first found in Brazil » 17:37
01/25/21
01/25
17:37
01/25/21
17:37
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$384.40 /

+1.55 (+0.40%)

, PFE

Pfizer

$37.28 /

+0.74 (+2.03%)

, BNTX

BioNTech

$110.62 /

+2.33 (+2.15%)

, MRNA

Moderna

$147.00 /

+15.95 (+12.17%)

, AZN

AstraZeneca

$54.02 /

+0.76 (+1.43%)

, JNJ

Johnson & Johnson

$165.91 /

+2.23 (+1.36%)

, NVAX

Novavax

$131.47 /

+4.48 (+3.53%)

The Minnesota Department…

The Minnesota Department of Health announced that its Public Health Laboratory has found the variant of the SARS-CoV-2 virus known as the Brazil P.1 variant in a specimen from a Minnesota resident with recent travel history to Brazil. While this variant is thought to be more transmissible than the initial strain of the virus that causes COVID-19 disease, it is not yet known whether the variant causes more severe illness. This case marks the first documented instance of the Brazil P.1 variant in the United States. The variant was found through the MDH's variant surveillance program. Each week this program collects 50 random samples from the University of Minnesota clinical laboratories, Infinity Biologix Laboratory in Oakdale, and other testing partners and then conducts special testing using a process called whole genome sequencing. Through this program, the state develops a more accurate picture of what specific forms of COVID-19 are circulating in Minnesota. Companies in the COVID-19 vaccine space include Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ), and Novavax (NVAX). Reference Link

ShowHide Related Items >><<
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

SPX S&P 500
$0.00 /

+ (+0.00%)

01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
SPY SPDR S&P 500 ETF Trust
$384.40 /

+1.55 (+0.40%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
MRNA Moderna
$147.00 /

+15.95 (+12.17%)

01/25/21 Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

01/22/21 Barclays
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays
01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
12/29/20 Piper Sandler
Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
NVAX Novavax
$131.47 /

+4.48 (+3.53%)

12/29/20 B. Riley Securities
Novavax selloff yesterday brings 'compelling' opportunity, says B. Riley
12/28/20 JPMorgan
JPMorgan sees data from Novavax vaccine trial in U.S. in March/April
12/14/20 Jefferies
Novavax initiated with a Buy at Jefferies
12/07/20 B. Riley Securities
Arcturus Therapeutics price target raised to $111 from $64 at B. Riley
PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

SPY SPDR S&P 500 ETF Trust
$384.40 /

+1.55 (+0.40%)

SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

SPY SPDR S&P 500 ETF Trust
$384.40 /

+1.55 (+0.40%)

SPX S&P 500
$0.00 /

+ (+0.00%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:43
01/25/21
01/25
16:43
01/25/21
16:43
GME

GameStop

$76.70 /

+11.97 (+18.49%)

, MRK

Merck

$81.15 /

+0.19 (+0.23%)

, MRNA

Moderna

$147.00 /

+15.95 (+12.17%)

, PFE

Pfizer

$37.28 /

+0.74 (+2.03%)

, NCR

NCR Corp.

$34.06 /

+0.64 (+1.92%)

, CATM

Cardtronics

$38.79 /

-2.11 (-5.16%)

, APO

Apollo Global

$45.87 /

-0.595 (-1.28%)

, SON

Sonoco

$61.25 /

+0.675 (+1.11%)

, CCK

Crown Holdings

$93.01 /

-0.67 (-0.72%)

, BBBY

Bed Bath & Beyond

$30.66 /

+0.43 (+1.42%)

, AMC

AMC Entertainment

$4.41 /

+0.885 (+25.14%)

, SOL

ReneSola

$26.20 /

-7.44 (-22.12%)

, GLUU

Glu Mobile

$9.14 /

-0.78 (-7.86%)

The major averages had a…

ShowHide Related Items >><<
SON Sonoco
$61.25 /

+0.675 (+1.11%)

SOL ReneSola
$26.20 /

-7.44 (-22.12%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NCR NCR Corp.
$34.06 /

+0.64 (+1.92%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

MRK Merck
$81.15 /

+0.19 (+0.23%)

GME GameStop
$76.70 /

+11.97 (+18.49%)

GLUU Glu Mobile
$9.14 /

-0.78 (-7.86%)

CCK Crown Holdings
$93.01 /

-0.67 (-0.72%)

CATM Cardtronics
$38.79 /

-2.11 (-5.16%)

BBBY Bed Bath & Beyond
$30.66 /

+0.43 (+1.42%)

APO Apollo Global
$45.87 /

-0.595 (-1.28%)

AMC AMC Entertainment
$4.41 /

+0.885 (+25.14%)

GME GameStop
$76.70 /

+11.97 (+18.49%)

01/25/21 KeyBanc
Bed Bath & Beyond activity being driven by Reddit message board, says KeyBanc
01/25/21
Fly Intel: Top five analyst downgrades
01/25/21 Telsey Advisory
GameStop continues surge despite double downgrade at Telsey Advisory
01/25/21 Telsey Advisory
GameStop downgraded to Underperform from Outperform at Telsey Advisory
MRK Merck
$81.15 /

+0.19 (+0.23%)

01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
01/20/21 Citi
Citi opens 'negative Catalyst Watch' on Bristol-Myers
01/06/21 Citi
Citi opens 'positive catalyst watch' on Merck
MRNA Moderna
$147.00 /

+15.95 (+12.17%)

01/25/21 Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
PFE Pfizer
$37.28 /

+0.74 (+2.03%)

01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
NCR NCR Corp.
$34.06 /

+0.64 (+1.92%)

01/11/21 Wells Fargo
Wells Fargo not ruling out counter-bid for Cardtronics slightly higher than $39
01/11/21 JPMorgan
NCR bid for Cardtronics makes sense, says JPMorgan
01/11/21 Stephens
NCR Corp. price target raised to $49 from $39 at Stephens
12/14/20 Craig-Hallum
Par Technology price target raised to $75 from $55 at Craig-Hallum
CATM Cardtronics
$38.79 /

-2.11 (-5.16%)

01/25/21 Truist
Cardtronics downgraded to Hold from Buy at Truist
APO Apollo Global
$45.87 /

-0.595 (-1.28%)

01/20/21 Truist
Athene Holding price target raised to $55 from $48 at Truist
01/11/21 Wells Fargo
Apollo Global price target raised to $55 from $50 at Wells Fargo
12/18/20 Deutsche Bank
Apollo Global price target raised to $51 from $49 at Deutsche Bank
11/06/20
Fly Intel: Top five analyst upgrades
SON Sonoco
$61.25 /

+0.675 (+1.11%)

01/20/21 Deutsche Bank
Sonoco price target raised to $61 from $52 at Deutsche Bank
11/17/20 Wells Fargo
Sonoco price target raised to $66 from $60 at Wells Fargo
11/11/20 BMO Capital
Sonoco stands to benefit from COVID-19 vaccine progress, says BMO Capital
10/23/20 BofA
Sonoco downgraded to Neutral from Buy at BofA
CCK Crown Holdings
$93.01 /

-0.67 (-0.72%)

01/20/21 Deutsche Bank
Crown Holdings price target raised to $112 from $104 at Deutsche Bank
01/11/21 Wells Fargo
Crown Holdings price target raised to $118 from $107 at Wells Fargo
01/07/21 Citi
Sealed Air upgraded to Buy from Neutral at Citi
12/15/20 Morgan Stanley
Crown Holdings upgraded to Overweight from Equal Weight at Morgan Stanley
BBBY Bed Bath & Beyond
$30.66 /

+0.43 (+1.42%)

01/25/21 Loop Capital
Bed Bath & Beyond price target raised to $30 from $18 at Loop Capital
01/08/21 Wedbush
Bed Bath & Beyond Q3 results 'mixed,' says Wedbush
01/08/21 Baird
Bed Bath & Beyond elevated to Fresh Pick at Baird
AMC AMC Entertainment
$4.41 /

+0.885 (+25.14%)

12/28/20 B. Riley Securities
'Wonder Women' opens well above expectations, says B. Riley Securities
12/04/20 B. Riley Securities
Theater selloff on Warner Bros. news likely an overreaction, says B. Riley
11/03/20 B. Riley Securities
AMC Entertainment price target lowered to $3.50 from $4.50 at B. Riley Securities
10/26/20 Citi
AMC Entertainment price target lowered to $3 from $4 at Citi
SOL ReneSola
$26.20 /

-7.44 (-22.12%)

12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
12/14/20 H.C. Wainwright
ReneSola price target raised to $12 from $4 at H.C. Wainwright
09/17/20 H.C. Wainwright
ReneSola initiated with a Buy at H.C. Wainwright
03/03/20
LD Micro to hold a virtual conference
GLUU Glu Mobile
$9.14 /

-0.78 (-7.86%)

01/24/21 Goldman Sachs
Glu Mobile downgraded to Neutral from Buy at Goldman Sachs
12/22/20 Morgan Stanley
Glu Mobile price target raised to $10.25 from $9.50 at Morgan Stanley
10/19/20 Cowen
COVID-19 continues to provide tailwind to mobile game spending, says Cowen
10/06/20 Piper Sandler
Piper Sandler teen survey shows increased video games engagement
SON Sonoco
$61.25 /

+0.675 (+1.11%)

SOL ReneSola
$26.20 /

-7.44 (-22.12%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NCR NCR Corp.
$34.06 /

+0.64 (+1.92%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

MRK Merck
$81.15 /

+0.19 (+0.23%)

GME GameStop
$76.70 /

+11.97 (+18.49%)

GLUU Glu Mobile
$9.14 /

-0.78 (-7.86%)

CCK Crown Holdings
$93.01 /

-0.67 (-0.72%)

CATM Cardtronics
$38.79 /

-2.11 (-5.16%)

BBBY Bed Bath & Beyond
$30.66 /

+0.43 (+1.42%)

APO Apollo Global
$45.87 /

-0.595 (-1.28%)

AMC AMC Entertainment
$4.41 /

+0.885 (+25.14%)

  • 04
    Jun
  • 19
    May
  • 12
    Feb
SON Sonoco
$61.25 /

+0.675 (+1.11%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NCR NCR Corp.
$34.06 /

+0.64 (+1.92%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

MRK Merck
$81.15 /

+0.19 (+0.23%)

GME GameStop
$76.70 /

+11.97 (+18.49%)

GLUU Glu Mobile
$9.14 /

-0.78 (-7.86%)

CCK Crown Holdings
$93.01 /

-0.67 (-0.72%)

BBBY Bed Bath & Beyond
$30.66 /

+0.43 (+1.42%)

APO Apollo Global
$45.87 /

-0.595 (-1.28%)

AMC AMC Entertainment
$4.41 /

+0.885 (+25.14%)

SOL ReneSola
$26.20 /

-7.44 (-22.12%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NCR NCR Corp.
$34.06 /

+0.64 (+1.92%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

MRK Merck
$81.15 /

+0.19 (+0.23%)

GME GameStop
$76.70 /

+11.97 (+18.49%)

GLUU Glu Mobile
$9.14 /

-0.78 (-7.86%)

CCK Crown Holdings
$93.01 /

-0.67 (-0.72%)

CATM Cardtronics
$38.79 /

-2.11 (-5.16%)

BBBY Bed Bath & Beyond
$30.66 /

+0.43 (+1.42%)

APO Apollo Global
$45.87 /

-0.595 (-1.28%)

AMC AMC Entertainment
$4.41 /

+0.885 (+25.14%)

SOL ReneSola
$26.20 /

-7.44 (-22.12%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

MRK Merck
$81.15 /

+0.19 (+0.23%)

GME GameStop
$76.70 /

+11.97 (+18.49%)

GLUU Glu Mobile
$9.14 /

-0.78 (-7.86%)

BBBY Bed Bath & Beyond
$30.66 /

+0.43 (+1.42%)

APO Apollo Global
$45.87 /

-0.595 (-1.28%)

AMC AMC Entertainment
$4.41 /

+0.885 (+25.14%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:18
01/25/21
01/25
12:18
01/25/21
12:18
MRK

Merck

$80.68 /

-0.28 (-0.35%)

, GME

GameStop

$95.00 /

+30.27 (+46.76%)

, MRNA

Moderna

$142.70 /

+11.65 (+8.89%)

, PFE

Pfizer

$36.94 /

+0.395 (+1.08%)

, NCR

NCR Corp.

$33.98 /

+0.56 (+1.68%)

, CATM

Cardtronics

$38.50 /

-2.4 (-5.87%)

, APO

Apollo Global

$46.02 /

-0.445 (-0.96%)

, BBBY

Bed Bath & Beyond

$34.03 /

+3.8 (+12.57%)

, BB

BlackBerry

$18.62 /

+4.59 (+32.72%)

, SOL

ReneSola

$26.72 /

-6.92 (-20.57%)

, MGNI

Magnite

$36.91 /

-3.175 (-7.92%)

The major averages are…

ShowHide Related Items >><<
SOL ReneSola
$26.72 /

-6.92 (-20.57%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
01/20/21 Citi
Citi opens 'negative Catalyst Watch' on Bristol-Myers
01/06/21 Citi
Citi opens 'positive catalyst watch' on Merck
GME GameStop
$95.00 /

+30.27 (+46.76%)

01/25/21
Fly Intel: Top five analyst downgrades
01/25/21 Telsey Advisory
GameStop continues surge despite double downgrade at Telsey Advisory
01/25/21 Telsey Advisory
GameStop downgraded to Underperform from Outperform at Telsey Advisory
01/13/21 Standpoint Research
GameStop downgraded to Hold from Buy at Standpoint Research
MRNA Moderna
$142.70 /

+11.65 (+8.89%)

01/25/21 Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
PFE Pfizer
$36.94 /

+0.395 (+1.08%)

01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

01/11/21 Wells Fargo
Wells Fargo not ruling out counter-bid for Cardtronics slightly higher than $39
01/11/21 JPMorgan
NCR bid for Cardtronics makes sense, says JPMorgan
01/11/21 Stephens
NCR Corp. price target raised to $49 from $39 at Stephens
12/14/20 Craig-Hallum
Par Technology price target raised to $75 from $55 at Craig-Hallum
CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

01/25/21 Truist
Cardtronics downgraded to Hold from Buy at Truist
APO Apollo Global
$46.02 /

-0.445 (-0.96%)

01/20/21 Truist
Athene Holding price target raised to $55 from $48 at Truist
01/11/21 Wells Fargo
Apollo Global price target raised to $55 from $50 at Wells Fargo
12/18/20 Deutsche Bank
Apollo Global price target raised to $51 from $49 at Deutsche Bank
11/06/20
Fly Intel: Top five analyst upgrades
BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

01/25/21 Loop Capital
Bed Bath & Beyond price target raised to $30 from $18 at Loop Capital
01/08/21 Wedbush
Bed Bath & Beyond Q3 results 'mixed,' says Wedbush
01/08/21 Baird
Bed Bath & Beyond elevated to Fresh Pick at Baird
01/05/21 Baird
Bed Bath & Beyond Q3 expectations remain low, says Baird
BB BlackBerry
$18.62 /

+4.59 (+32.72%)

12/18/20 TD Securities
BlackBerry price target raised to $8.50 from $5.50 at TD Securities
12/15/20 RBC Capital
BlackBerry price target raised to $7.50 from $5 at RBC Capital
12/15/20 RBC Capital
BlackBerry price target raised to $7.50 from $5.00 at RBC Capital
12/01/20 TD Securities
BlackBerry jump on AWS pact looks like overreaction, says TD Securities
SOL ReneSola
$26.72 /

-6.92 (-20.57%)

12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
12/14/20 H.C. Wainwright
ReneSola price target raised to $12 from $4 at H.C. Wainwright
09/17/20 H.C. Wainwright
ReneSola initiated with a Buy at H.C. Wainwright
03/03/20
LD Micro to hold a virtual conference
MGNI Magnite
$36.91 /

-3.175 (-7.92%)

01/24/21 Truist
Magnite downgraded to Hold from Buy at Truist
01/22/21 Craig-Hallum
Magnite price target raised to $45 from $25 at Craig-Hallum
01/11/21 Susquehanna
Magnite weakness a buying opportunity, says Susquehanna
12/21/20 Needham
Magnite price target raised to $30 from $18 at Needham
SOL ReneSola
$26.72 /

-6.92 (-20.57%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

  • 19
    May
  • 12
    Feb
PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

SOL ReneSola
$26.72 /

-6.92 (-20.57%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

SOL ReneSola
$26.72 /

-6.92 (-20.57%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

Options
Moderna call volume above normal and directionally bullish » 10:05
01/25/21
01/25
10:05
01/25/21
10:05
MRNA

Moderna

$145.00 /

+13.95 (+10.64%)

Bullish option flow…

Bullish option flow detected in Moderna with 12,881 calls trading, 1.0x expected, and implied vol increasing almost 5 points to 77.49%. Feb-21 125 puts and 1/29 weekly 150 calls are the most active options, with total volume in those strikes near 6,100 contracts. The Put/Call Ratio is 0.57. Earnings are expected on February 24th.

ShowHide Related Items >><<
MRNA Moderna
$145.00 /

+13.95 (+10.64%)

MRNA Moderna
$145.00 /

+13.95 (+10.64%)

01/25/21 Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
MRNA Moderna
$145.00 /

+13.95 (+10.64%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$145.00 /

+13.95 (+10.64%)

MRNA Moderna
$145.00 /

+13.95 (+10.64%)

MRNA Moderna
$145.00 /

+13.95 (+10.64%)

Downgrade
Fly Intel: Top five analyst downgrades » 09:52
01/25/21
01/25
09:52
01/25/21
09:52
GME

GameStop

$87.80 /

+23.07 (+35.64%)

, WMT

Walmart

$145.08 /

-1.36 (-0.93%)

, DDD

3D Systems

$35.99 /

+1.535 (+4.46%)

, ALNY

Alnylam

$171.50 /

-0.875 (-0.51%)

, BOX

Box

$17.54 /

-0.31 (-1.74%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GameStop (GME) double downgraded to Underperform from Outperform at Telsey Advisory with analyst Joseph Feldman saying he sees a "disconnect" between GameStop's fundamentals and its valuation following the recent surge in the shares. 2. Walmart (WMT) downgraded to Sell from Hold at R5 Capital with analyst Scott Mushkin saying his visits to approximately 40 supercenters across multiple states revealed four "long-term fundamental problems" he sees the company needing to fix; its freshness standards need a significant upgrade; its out-of-stocks, overstocks and understocks must all be addressed and corrected; and more capital needs to be invested, particularly to improve its omnichannel offerings. 3. 3D Systems (DDD) downgraded to Hold from Buy at Berenberg with analyst Kenneth Vallace saying the risk/reward is less favorable following the stock's recent rally. 4. Alnylam (ALNY) downgraded to Market Perform from Outperform at BMO Capital with analyst Do Kim saying given the stock's 35% single-week run-up in early January and "limited" catalysts to drive further "meaningful" upside this year, Alnylam shares look "fairly valued." 5. Box (BOX) downgraded to Neutral from Buy at DA Davidson with analyst Rishi Jaluria citing the company's low scores in his CIO survey for 2021 spending intentions, competitive pressure from Microsoft's (MSFT) One Drive and a "more muted" margin expansion as COVID-related cost savings start to fade. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WMT Walmart
$145.08 /

-1.36 (-0.93%)

GME GameStop
$87.80 /

+23.07 (+35.64%)

DDD 3D Systems
$35.99 /

+1.535 (+4.46%)

BOX Box
$17.54 /

-0.31 (-1.74%)

ALNY Alnylam
$171.50 /

-0.875 (-0.51%)

GME GameStop
$87.80 /

+23.07 (+35.64%)

01/25/21 Telsey Advisory
GameStop continues surge despite double downgrade at Telsey Advisory
01/25/21 Telsey Advisory
GameStop downgraded to Underperform from Outperform at Telsey Advisory
01/13/21 Standpoint Research
GameStop downgraded to Hold from Buy at Standpoint Research
01/11/21 Benchmark
Benchmark 'not surprised' by GameStop board change after 'disappointing' holiday
WMT Walmart
$145.08 /

-1.36 (-0.93%)

01/25/21 R5 Capital
R5 Capital downgrades 'operationally challenged' Walmart to Sell
01/25/21 R5 Capital
Walmart downgraded to Sell from Hold at R5 Capital
01/22/21 Jefferies
Walmart has upside potential to $200 per share, says Jefferies
01/20/21 Cleveland Research
Walmart U.S. sales, share appear to be improving, says Cleveland Research
DDD 3D Systems
$35.99 /

+1.535 (+4.46%)

01/25/21 Berenberg
3D Systems downgraded to Hold from Buy at Berenberg
01/25/21 Berenberg
3D Systems downgraded to Hold from Buy at Berenberg
01/19/21
Fly Intel: Top five analyst initiations
01/19/21 Stifel
3D Systems initiated with a Hold at Stifel
ALNY Alnylam
$171.50 /

-0.875 (-0.51%)

01/25/21 BMO Capital
Alnylam downgraded to Market Perform from Outperform at BMO Capital
01/25/21 BMO Capital
Alnylam downgraded to Market Perform from Outperform at BMO Capital
01/13/21 Cowen
Alnylam price target raised to $197 from $154 at Cowen
01/11/21 B. Riley Securities
Dicerna price target raised to $37 from $30 at B. Riley Securities
BOX Box
$17.54 /

-0.31 (-1.74%)

01/25/21 DA Davidson
Box downgraded to Neutral from Buy at DA Davidson
08/27/20 Craig-Hallum
Box price target raised to $30 from $24 at Craig-Hallum
08/27/20 Morgan Stanley
Box has large, attractive market opportunity, says Morgan Stanley
05/28/20 Raymond James
Box price target raised to $24 from $18 at Raymond James
WMT Walmart
$145.08 /

-1.36 (-0.93%)

GME GameStop
$87.80 /

+23.07 (+35.64%)

DDD 3D Systems
$35.99 /

+1.535 (+4.46%)

BOX Box
$17.54 /

-0.31 (-1.74%)

ALNY Alnylam
$171.50 /

-0.875 (-0.51%)

WMT Walmart
$145.08 /

-1.36 (-0.93%)

GME GameStop
$87.80 /

+23.07 (+35.64%)

ALNY Alnylam
$171.50 /

-0.875 (-0.51%)

WMT Walmart
$145.08 /

-1.36 (-0.93%)

GME GameStop
$87.80 /

+23.07 (+35.64%)

DDD 3D Systems
$35.99 /

+1.535 (+4.46%)

BOX Box
$17.54 /

-0.31 (-1.74%)

ALNY Alnylam
$171.50 /

-0.875 (-0.51%)

WMT Walmart
$145.08 /

-1.36 (-0.93%)

GME GameStop
$87.80 /

+23.07 (+35.64%)

DDD 3D Systems
$35.99 /

+1.535 (+4.46%)

BOX Box
$17.54 /

-0.31 (-1.74%)

Recommendations
Piper reiterates $170 target on Moderna with vaccine active on new strains » 09:47
01/25/21
01/25
09:47
01/25/21
09:47
MRNA

Moderna

$141.57 /

+10.52 (+8.03%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $170 price target after the company announced that mRNA-1273 retained activity and produced neutralizing titers against emerging SARS-CoV-2 variants including the U.K. strain B.1.1.7 and South Africa strain B.1.351. No significant impact on neutralizing titers against the B.1.1.7 variant was observed, although a six-fold reduction in neutralizing titers was observed with the B.1.351 variant versus. prior strains, Tenthoff tells investors in a research note. Despite the slow vaccination pace, Moderna expects to deliver 200M mRNA-1273 doses in the U.S. by end of Q2, and 600M to to 1B doses globally by the end of 2021, the analyst points out. He thinks the SARS-CoV-2 booster vaccine will be able to further boost any of the leading vaccine candidates, which "could provide a revenue tail" for mRNA-1273.

ShowHide Related Items >><<
MRNA Moderna
$141.57 /

+10.52 (+8.03%)

MRNA Moderna
$141.57 /

+10.52 (+8.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
MRNA Moderna
$141.57 /

+10.52 (+8.03%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$141.57 /

+10.52 (+8.03%)

MRNA Moderna
$141.57 /

+10.52 (+8.03%)

MRNA Moderna
$141.57 /

+10.52 (+8.03%)

Hot Stocks
Moderna announces results from COVID-19 Vaccine study against new strains » 08:32
01/25/21
01/25
08:32
01/25/21
08:32
MRNA

Moderna

$131.01 /

-1.97 (-1.48%)

Moderna announced results…

Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively. The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective. This study was conducted in collaboration with the Vaccine Research Center, or VRC, at the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, or NIH. The manuscript has been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication. The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 microgram dose is expected to be protective against emerging strains detected to date. Nonetheless, Moderna announced its clinical strategy to proactively address the pandemic as the virus continues to evolve. First, the company will test an additional booster dose of its COVID-19 Vaccine to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Second, the company is advancing an emerging variant booster candidate against the B.1.351 variant first identified in the Republic of South Africa. The company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the U.S. to evaluate the immunological benefit of boosting with strain-specific spike proteins. Moderna expects that its mRNA-based booster vaccine will be able to further boost neutralizing titers in combination with all of the leading vaccine candidates. First detected in September 2020 in the United Kingdom, the SARS-CoV-2 B.1.1.7 variant has seventeen mutations in the viral genome with eight mutations located in the spike, or S, protein. The B.1.351 variant, first detected in South Africa, has ten mutations located in the spike S protein. Both variants have spread at a rapid rate and are associated with increased transmission and a higher viral burden after infection. The in vitro study assessed the ability of mRNA-1273 to elicit potently neutralizing antibodies against the new SARS-CoV-2 variants, using sera from eight Phase 1 clinical trial participants who received two 100 microgram doses of mRNA-1273, and separately using sera from non-human primates, or NHPs, immunized with two doses of 30 microgram or 100 microgram of mRNA-1273. For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants. For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While thecCompany expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.

ShowHide Related Items >><<
MRNA Moderna
$131.01 /

-1.97 (-1.48%)

MRNA Moderna
$131.01 /

-1.97 (-1.48%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
MRNA Moderna
$131.01 /

-1.97 (-1.48%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$131.01 /

-1.97 (-1.48%)

MRNA Moderna
$131.01 /

-1.97 (-1.48%)

MRNA Moderna
$131.01 /

-1.97 (-1.48%)

Downgrade
Alnylam downgraded to Market Perform from Outperform at BMO Capital » 06:25
01/25/21
01/25
06:25
01/25/21
06:25
ALNY

Alnylam

$172.42 /

+5.75 (+3.45%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim downgraded Alnylam to Market Perform from Outperform with an unchanged $185 price target. Given the stock's 35% single-week run-up in early January and "limited" catalysts to drive further "meaningful" upside this year, Alnylam shares look "fairly valued", the analyst tells investors in a research note. Vutrisiran HELIOS-A data and Alnylam's 5-year strategy has priced in commercial execution of its drugs for the intermediate term, Kim adds.

ShowHide Related Items >><<
ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

01/25/21 BMO Capital
Alnylam downgraded to Market Perform from Outperform at BMO Capital
01/13/21 Cowen
Alnylam price target raised to $197 from $154 at Cowen
01/11/21 B. Riley Securities
Dicerna price target raised to $37 from $30 at B. Riley Securities
12/21/20 RBC Capital
Alnylam price target lowered to $144 from $150 at RBC Capital
ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

Downgrade
Alnylam downgraded to Market Perform from Outperform at BMO Capital » 05:36
01/25/21
01/25
05:36
01/25/21
05:36
ALNY

Alnylam

$172.42 /

+5.75 (+3.45%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim downgraded Alnylam Pharmaceuticals to Market Perform from Outperform with an $185 price target.

ShowHide Related Items >><<
ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

01/13/21 Cowen
Alnylam price target raised to $197 from $154 at Cowen
01/11/21 B. Riley Securities
Dicerna price target raised to $37 from $30 at B. Riley Securities
12/21/20 RBC Capital
Alnylam price target lowered to $144 from $150 at RBC Capital
12/20/20 Piper Sandler
Inclisiran CRL 'a surprise,' not big negative for Alnylam, says Piper Sandler
ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

ALNY Alnylam
$172.42 /

+5.75 (+3.45%)

Friday
Recommendations
Autodesk price target raised to $360 from $295 at Argus » 07:55
01/22/21
01/22
07:55
01/22/21
07:55
ADSK

Autodesk

$306.43 /

-2.24 (-0.73%)

Argus analyst Joseph…

Argus analyst Joseph Bonner raised the firm's price target on Autodesk to $360 from $295 and keeps a Buy rating on the shares. The impact of the pandemic has continued to slow Autodesk's growth in its "critical" U.S. and UK markets, but other parts of its global business have "picked up substantially" from the COVID-19 trough, the analyst tells investors in a research note. Bonner adds that Autodesk valuations are high, but the company offers a "highly differentiated" software product.

ShowHide Related Items >><<
ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

01/21/21 Goldman Sachs
Autodesk initiated with a Sell at Goldman Sachs
01/15/21 Deutsche Bank
Autodesk price target raised to $370 from $300 at Deutsche Bank
01/06/21 Barclays
Autodesk price target raised to $324 from $295 at Barclays
01/05/21 KeyBanc
Autodesk price target raised to $345 from $310 at KeyBanc
ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.